Fornaro L, Leone F, Vienot A, et al. - Among 137 metastatic (MPC)/locally advanced unresectable (LAPC) patients treated with triplet chemotherapy, researchers examined the putative prognostic factors in order to recognize patients with superior outcomes who were treated with FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) for MPC/LAPC and to determine the risk of death. Four variables, ie, performance status, liver metastases, baseline carbohydrate antigen 19-9 level, and neutrophil-to-lymphocyte ratio were discovered by multivariate analysis, to be related to 6-month survival or had adequate clinical plausibility to be incorporated in the nomogram. Exactitude was verified in the validation cohort. Subsequent to categorizing all cases, four subsets with various outcomes were recognized by 0, 1, 2, or > 2 poor prognostic characteristics. Hence, in the first 6 months following initiation of FOLFIRINOX, the nomogram that was made explicitly prognosticates the risk of death in MPC/LAPC individuals. Moreover, this tool could be beneficial in order to supervise communication about prognosis and to notify the design and explanation of clinical trials.